Prevention of experimental thrombosis of the coronary artery, in anesthetized dogs, with a low molecular weight heparin, enoxaparine (PK 10169)
Uzan, A.; Clairefond, P.; Mardiguian, J.; Trillou, M.; Le Fur, G.; Mestre, M.
Annales Pharmaceutiques Francaises 43(6): 539-546
1985
ISSN/ISBN: 0003-4509 PMID: 3838029 Document Number: 243294
Enoxaparine (PK 10169), a low molecular weight heparin, unlike heparin itself, induces, in vitro and in vivo, an anticoagulant effect clearly lower than its anti Xa activity. The antithrombotic activity of this compound has been studied in the anaesthetized dog, using as a model the arterial thrombosis induced by electrical stimulation (150 .mu.A) for 6 hours of the coronary artery. Following subcutaneous injection, enoxaparine prevents thrombus growth from 0.625 mg/kg, with a maximum effect at 2.5 mg/kg. In control animals, coronary blood flow is reduced markedly due to the thrombose. The reduction in blood flow does not occur in the treated animals (2.5 mg/kg s.c.). The antithrombotic activity of enoxaparine is not accompanied by any change in the total coagulation time or the HOWELL time even though Xa activity is strongly inhibited. I.v. injection of enoxaparine (2.5 mg/kg) prevents thrombus growth with a clear dissociation between anti Xa and anti IIa effects. A low molecular weight heparin seems, therefore, efficacious in preventing coronary thrombus development, without affecting blood coagulation.